Taysha Gene Therapies, Inc.
Close on Oct 19, 2026
- Market cap
- $1.45B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | During market hours | – | $-0.13 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | – | $-0.12 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | $2.30M | $-0.08 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | During market hours | – | – | – |
Press releases
Announcements Taysha Gene Therapies filed with the SEC
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.2 to Form 8-K
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TSHA-102 Rett Syndrome program Update:
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Material agreement · Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the
Other events · EX-99.1 to Form 8-K
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase
Other events · EX-99.1 to Form 8-K
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
We are a clinical-stage biotechnology
Material agreement · Other events · EX-99.2 to Form 8-K
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.3 to Form 8-K
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K/A
Legal disclosure FORWARD LOOKING STATEMENTS This presentation contains
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K/A
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TSHA-102 Rett Syndrome Program Update
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Results of operations · Other events · EX-99.1 to Form 8-K
We are a clinical-stage biotechnology
Results of operations · Other events · EX-99.2 to Form 8-K
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2
Regulation FD disclosure · EX-99.1 to Form 8-K
TSHA-102 in clinical evaluation for
Regulation FD disclosure · EX-99.2 to Form 8-K
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2
Regulation FD disclosure · EX-99.1 to Form 8-K
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical
Results of operations · EX-99.1 to Form 8-K
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult
Regulation FD disclosure · EX-99.1 to Form 8-K
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)
Other events · EX-99.1 to Form 8-K
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
Other events · EX-99.1 to Form 8-K
Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in
Material agreement · Results of operations · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Taysha Gene Therapies Announces $150 Million Private Placement Financing
Material agreement · Results of operations · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett
Regulation FD disclosure · EX-99.1 to Form 8-K
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in
Regulation FD disclosure · EX-99.1 to Form 8-K
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial
Other events · EX-99.1 to Form 8-K